Conditions: Follicular Lymphoma
Keywords: Non-Hodgkin's Lymphoma Follicular Non-Hodgkin's Lymphoma Lymphoma
Allocation: NON_RANDOMIZED | Intervention model: SINGLE_GROUP
Enrollment: 1
Healthy volunteers: no

Brief summary:
The purpose of this study is to determine what dose of bortezomib in combination with tositumomab I-131 is tolerable whether bortezomib and Tositumomab I-131 are effective in the treatment of relapsed or refractory non-hodgkin's lymphoma (NHL). Both agents are effective in treating relapsed and refractory NHL. Administer of the agents together may sensitize the cells to the radiation from Tositumomab I-131.

Detailed description:

Arms:
arm 1: None

Interventions: intervention 1: Bortezomib and Tositumomab I-131
Intervention descriptions: intervention 1: None

Protocol document: